FEB 27, 2019 10:30 AM PST

The Current State-of-the-Art Tissue Expression Analysis Platform for Detection & Quantification of Target & Biomarker mRNAs, Splice Variants and Mutations in Preclinical & Clinical Tissues

Presented at: Drug Discovery 2019
Speaker
  • Vice President of Business Development, Advanced Cell Diagnostics
    Biography
      Dr. Christopher Bunker is the Vice President of Business Development at Advanced Cell Diagnostics (ACD) in Newark, California. Dr. Bunker completed his doctoral research in Biological Chemistry at Harvard University and a Leukemia Society of America postdoctoral fellowship in molecular genetics at UCSF. He was a senior scientist in cancer functional genomics at Genome Therapeutics before joining Cell Signaling Technology at its inception in 2000. Dr. Bunker received an M.B.A from Boston University. He joined ACD in 2010, where he has led its assay services business for the past 8 years.

    Abstract

    Advanced Cell Diagnostics’ RNAscope products and assay services are utilized widely for tissue-based gene expression analysis in early target validation, preclinical animal efficacy and safety studies and in biomarker development.  RNAscope is clinically validated and performs reliably on routine FFPE archival human tissues and clinical biopsies and any animal model tissues.  Detection limits are at single molecule level, enabling quantitative, cell-specific expression analysis within tissue microenvironments.  There are over 15,000 RNAscope probes in use and over 1,800 publications – more than 2-per-day.  Continuing advances in ACD RNA ISH technology are enable a wide range of applications, including:

    -    Multiplexed RNA ISH
    -    Dual ISH/IHC for target analysis combined with cell marker staining
    -    Isoform-specific assays with exon junction probes
    -    Tissue-based gene edit detection
    -    Viral RNA and DNA genome detection
    -    AAV gene therapy biodistribution analysis
    -    CAR-TCR T cell detection and tumor infiltration assays with lentiviral probes

    RNAscope technologies are enabling faster and more rigorous tissue-based target and biomarker research with cell-specific, single-molecule sensitive RNA detection in the context of complex disease microenvironments.  The technology, methods and its applications will be illustrated.

    Learning Objectives:

    1. How RNAscope® in situ hybridization is utilized for tissue-based, cell-specific expression analysis
    2. How RNAscope® is enabling gene therapy and cell therapy tissue biodistribution analysis


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    MAY 08, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    Loading Comments...
    Show Resources
    Attendees